- Home
- VYNE vs COEP Comparison
VYNE vs COEP Comparison
Compare VYNE & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VYNE
- COEP
- Stock Information
- Founded
- VYNE 2003
- COEP 2017
- Country
- VYNE United States
- COEP United States
- Employees
- VYNE N/A
- COEP N/A
- Industry
- VYNE Biotechnology: Pharmaceutical Preparations
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VYNE Health Care
- COEP Health Care
- Exchange
- VYNE Nasdaq
- COEP Nasdaq
- Market Cap
- VYNE 35.7M
- COEP 32.0M
- IPO Year
- VYNE 2018
- COEP N/A
- Fundamental
- Price
- VYNE $0.94
- COEP $9.46
- Analyst Decision
- VYNE Strong Buy
- COEP
- Analyst Count
- VYNE 2
- COEP 0
- Target Price
- VYNE $6.25
- COEP N/A
- AVG Volume (30 Days)
- VYNE 259.3K
- COEP 31.8K
- Earning Date
- VYNE 05-08-2025
- COEP 05-14-2025
- Dividend Yield
- VYNE N/A
- COEP N/A
- EPS Growth
- VYNE N/A
- COEP N/A
- EPS
- VYNE N/A
- COEP N/A
- Revenue
- VYNE $605,000.00
- COEP $62,874.00
- Revenue This Year
- VYNE N/A
- COEP N/A
- Revenue Next Year
- VYNE N/A
- COEP N/A
- P/E Ratio
- VYNE N/A
- COEP N/A
- Revenue Growth
- VYNE 43.03
- COEP N/A
- 52 Week Low
- VYNE $0.95
- COEP $2.31
- 52 Week High
- VYNE $4.30
- COEP $13.70
- Technical
- Relative Strength Index (RSI)
- VYNE 25.37
- COEP 49.55
- Support Level
- VYNE $0.96
- COEP $9.14
- Resistance Level
- VYNE $1.09
- COEP $9.85
- Average True Range (ATR)
- VYNE 0.08
- COEP 0.53
- MACD
- VYNE -0.01
- COEP -0.02
- Stochastic Oscillator
- VYNE 3.42
- COEP 34.59
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.